NDA 7942, held by Forest Labs. Epinephrine.
As of Nov 15, 2026, NDA 7942 (Sus-Phrine Sulfite Free), held by Forest Labs, was first approved by FDA on Jun 8, 1951, with 14 approved supplements and 0 published complete response letters.
| Dec 7, 2007 | Supplement 1Efficacy (new indication or use) | Approved | None posted |
| Jun 8, 1951 | Original applicationNew formulation or manufacturer · Standard review | Approved | None posted |
| Sus-Phrine Sulfite Free5MG/ML · injectable;injection | Epinephrine | Discontinued |
| Sus-Phrine Sulfite Free1.5MG/AMP · injectable;injection | Epinephrine | Discontinued |
| Dec 7, 2007 | Supplement 1Efficacy (new indication or use) | Approved | None posted |
| Dec 7, 2007 | Supplement 9Labeling | Approved | None posted |
| Dec 7, 2007 | Supplement 12Labeling | Approved | None posted |
| Feb 5, 1999 | Supplement 16Labeling · Standard review | Approved | None posted |
| Oct 7, 1998 | Supplement 17Manufacturing · Standard review | Approved | None posted |
| Feb 8, 1995 | Supplement 15Manufacturing · Standard review | Approved | None posted |
| Dec 20, 1993 | Supplement 14Labeling | Approved | None posted |
| Jan 19, 1990 | Supplement 11Manufacturing · Standard review | Approved | None posted |
| Nov 19, 1986 | Supplement 6Manufacturing · Standard review | Approved | None posted |
| Oct 16, 1985 | Supplement 8Manufacturing · Standard review | Approved | None posted |
| Dec 6, 1984 | Supplement 7Manufacturing · Standard review | Approved | None posted |
| Oct 26, 1983 | Supplement 2Manufacturing · Standard review | Approved | None posted |
| Oct 26, 1983 | Supplement 3Labeling | Approved | None posted |
| Oct 26, 1983 | Supplement 5Labeling | Approved | None posted |
| Jun 8, 1951 | Original applicationNew formulation or manufacturer · Standard review | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters